Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Given New $54.00 Price Target at Jefferies Financial Group

Key Points

• Jefferies Financial Group raised its price target for Kiniksa Pharmaceuticals International from $45.00 to $54.00, indicating a potential upside of **77.81%** from the current price.
• Wells Fargo upgraded its rating to "overweight" with a new price target of **$42.00**, while seven analysts currently rate Kiniksa as a buy.
• Kiniksa Pharmaceuticals reported **$0.23 EPS** for the last quarter, surpassing estimates, though it faces negative net margins and a projected **-0.55 EPS** for the fiscal year.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) had its price target boosted by equities researchers at Jefferies Financial Group from $45.00 to $54.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage presently has a "buy" rating on the stock. Jefferies Financial Group's price objective would suggest a potential upside of 77.81% from the company's current price.

A number of other brokerages also recently commented on KNSA. Wells Fargo & Company increased their price target on shares of Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the company an "overweight" rating in a report on Wednesday, July 9th. Wall Street Zen raised shares of Kiniksa Pharmaceuticals International from a "hold" rating to a "buy" rating in a report on Sunday, July 6th. Finally, Wedbush reaffirmed an "outperform" rating and issued a $36.00 price target on shares of Kiniksa Pharmaceuticals International in a report on Monday, July 21st. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat, Kiniksa Pharmaceuticals International presently has an average rating of "Buy" and an average price target of $41.17.

Kiniksa Pharmaceuticals International Stock Performance

Shares of KNSA traded up $3.33 during midday trading on Tuesday, hitting $30.37. 1,678,912 shares of the company traded hands, compared to its average volume of 692,442. The firm has a 50 day moving average of $28.04 and a 200-day moving average of $23.80. Kiniksa Pharmaceuticals International has a 52 week low of $17.82 and a 52 week high of $31.92. The stock has a market cap of $2.22 billion, a price-to-earnings ratio of -121.48 and a beta of 0.05.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last released its quarterly earnings data on Tuesday, July 29th. The company reported $0.23 EPS for the quarter, beating the consensus estimate of $0.08 by $0.15. Kiniksa Pharmaceuticals International had a negative net margin of 3.52% and a negative return on equity of 3.83%. Sell-side analysts predict that Kiniksa Pharmaceuticals International will post -0.55 earnings per share for the current fiscal year.

Insider Activity

In other Kiniksa Pharmaceuticals International news, Director Barry D. Quart sold 12,336 shares of the firm's stock in a transaction dated Wednesday, June 11th. The shares were sold at an average price of $30.39, for a total value of $374,891.04. Following the completion of the sale, the director owned 12,546 shares of the company's stock, valued at $381,272.94. This trade represents a 49.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO Michael R. Megna sold 15,211 shares of the firm's stock in a transaction that occurred on Tuesday, June 3rd. The stock was sold at an average price of $28.75, for a total transaction of $437,316.25. Following the transaction, the chief accounting officer directly owned 32,546 shares in the company, valued at approximately $935,697.50. This trade represents a 31.85% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 365,469 shares of company stock worth $10,413,279 in the last ninety days. 53.48% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals International

Institutional investors have recently modified their holdings of the stock. Cannon Global Investment Management LLC bought a new position in shares of Kiniksa Pharmaceuticals International during the second quarter valued at approximately $479,000. Nordea Investment Management AB boosted its stake in shares of Kiniksa Pharmaceuticals International by 1.6% during the second quarter. Nordea Investment Management AB now owns 130,160 shares of the company's stock valued at $3,582,000 after purchasing an additional 2,110 shares in the last quarter. Robeco Institutional Asset Management B.V. bought a new position in shares of Kiniksa Pharmaceuticals International during the second quarter valued at approximately $233,000. Toth Financial Advisory Corp bought a new position in shares of Kiniksa Pharmaceuticals International during the second quarter valued at approximately $296,000. Finally, Wealth Enhancement Advisory Services LLC boosted its stake in shares of Kiniksa Pharmaceuticals International by 13.6% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 15,410 shares of the company's stock valued at $430,000 after purchasing an additional 1,846 shares in the last quarter. 53.95% of the stock is owned by hedge funds and other institutional investors.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.